Weight loss jabs are no quick fix, health boss warns
Lancashire's director of public health says there needs to a wider conversation about healthy eating.
www.bbc.comHere are the latest widely reported developments on weight loss jabs as of 2026:
-
UK regulator approves a stronger Wegovy dose: The MHRA approved a higher weekly dose (7.2 mg) of Wegovy, with claims of around 20% average weight loss in obesity trials, and a subset achieving over 25% weight loss at 72 weeks. Side effects were mainly GI in nature. This marks a step up in availability and potential effectiveness for adults with obesity in the UK.[1]
-
New anti-obesity candidates moving toward later-stage testing: Reports from major outlets in late 2025 and early 2026 highlighted ongoing Phase 2/3 work on next-generation peptides (and combination approaches) aiming to broaden mechanisms beyond current GLP-1 class drugs, with timelines pointing to Phase 3 initiation within the year in some programs.[2]
-
WHO stance toward weight loss injections: The World Health Organization signaled conditional backing for weight loss injections as part of obesity management, while emphasising guidelines for use in children and adolescents and the need for integrated care approaches; this reflects growing international policy interest in pharmacotherapy as part of obesity strategies.[3]
-
Real-world uptake and access in health systems: Several reports describe increasing access to these injections via general practice in some regions (e.g., parts of England) and ongoing debates about long-term safety, sustainability, and the risk of weight regain after stopping treatment. Public health voices stress that pharmacotherapy should complement, not replace, lifestyle interventions.[7][9]
-
Rebound and long-term considerations: Emerging analyses indicate that weight loss from injections can be substantial but weight often rebounds after stopping treatment, with studies noting ongoing monitoring and support are important for durable outcomes. Health experts caution that this is not a one-time fix and emphasize comprehensive weight management plans.[8][10]
Illustration: Consider Wegovy’s higher-dose option as a potential catalyst for greater initial weight loss, while recognizing that sustained results depend on ongoing lifestyle support and, for many patients, potential discontinuation challenges.
Citations:
- Wegovy higher-dose UK approval and efficacy claims.[1]
- Ongoing development of new obesity drugs and Phase 3 timelines.[2]
- WHO conditional backing and guidance considerations.[3]
- England GP access and broader adoption discussions.[7]
- Long-term safety and rebound concerns in public discourse.[10][8]